Assembly Biosciences (NASDAQ:ASMB) Stock Crosses Above 200 Day Moving Average – Here’s Why

Assembly Biosciences, Inc. (NASDAQ:ASMB)’s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $28.97 and traded as high as $29.01. Assembly Biosciences shares last traded at $28.75, with a volume of 142,905 shares traded.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Mizuho set a $40.00 price objective on shares of Assembly Biosciences and gave the stock an “outperform” rating in a research note on Thursday, November 20th. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a report on Monday, December 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, January 21st. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Assembly Biosciences has an average rating of “Moderate Buy” and an average target price of $41.75.

Assembly Biosciences Price Performance

The stock’s 50 day simple moving average is $29.87 and its two-hundred day simple moving average is $28.97. The company has a market capitalization of $454.83 million, a P/E ratio of -6.00 and a beta of 1.13.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Bank of America Corp DE raised its position in shares of Assembly Biosciences by 6,382.7% during the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 3,319 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 6,823 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in Assembly Biosciences in the fourth quarter worth about $228,000. Virtus Investment Advisers LLC bought a new stake in Assembly Biosciences during the 4th quarter worth about $251,000. Finally, Qube Research & Technologies Ltd bought a new stake in Assembly Biosciences during the 3rd quarter worth about $282,000. 19.92% of the stock is currently owned by institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.